A Phase I Open-label Pharmacokinetics And Safety Study Of Talazoparib (mdv3800) In Patients With Advanced Solid Tumors And Normal Or Varying Degrees Of Renal Impairment
Phase of Trial: Phase I
Latest Information Update: 14 Sep 2017
At a glance
- Drugs Talazoparib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Pfizer
- 27 Jul 2017 Status changed from not yet recruiting to recruiting.
- 27 Jul 2017 Planned primary completion date changed from 1 Jan 2018 to 19 Dec 2017.
- 21 Dec 2016 New trial record